A benefit-risk assessment of extended-release oxybutynin

Drug Safety

Volumn 25, Issue 12, 2002, Pages 867-876

  Michel, Martin C ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MUSCARINIC RECEPTOR BLOCKING AGENT; N DESETHYLOXYBUTYNIN; OXYBUTYNIN; PROPIVERINE; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUSTAINED RELEASE PREPARATION; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0036398046     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225120-00004     Document Type: Review

References (40)

1. Hunskaar S, Arnold EP, Burgio K, et al. Epidemiology and natural history of urinary incontinence (UI). In: Abrams P, Khoury S, Wein A, editors. Incontinence. Plymouth: Plymbridge Distributors Ltd, 1999: 197-226
2. Goepel M, Hoffmann J, Piro M, et al. Prevalence and physician awareness of symptoms of urinary bladder dysfunction. Eur Urol 2002; 41: 234-9
3. Bulmer P, Abrams P. The overactive bladder. Rev Contemp Pharmacother 2000; 11: 1-11
4. Wyndaele JJ. The overactive bladder. BJU Int 2001; 88: 135-40
5. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? a population-based prevalence study. BJU Int 2001; 87: 760-6
6. Luscombe FA. Socioeconomic burden of urinary incontinence with focus on overactive bladder and tolterodine treatment. Rev Contemp Pharmacother 2000; 11: 43-62
7. Andersson K-E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-308
8. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 Suppl. 5A: 33-46
9. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-62
10. Andersson K-E, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001; 19: 319-23
11. Malone-Lee JG. The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive/unstable bladder. Rev Contemp Pharmacother 2000; 11: 29-42
12. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999; 39: 289-96
13. Sathyan G, Chancellor MB, Gupta SK. Effects of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001; 52: 409-17
14. Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000; 16: 149-55
15. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515-20
16. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22: 859-69
17. Caulfield MP, Birdsall NJ. International Union of Pharmacology: XVII. classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90
18. Wang P. Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995; 273: 959-66
19. Goepel M, Gronewald A, Krege S, et al. Muscarinic receptor subtypes in porcine detmsor: comparison with humans and regulation by bladder augmentation. Urol Res 1998; 26: 149-54
20. Yamanishi T, Chapple CR, Yasuda K, et al. The role of M2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br J Pharmacol 2000; 131: 1482-8
21. Hegde SS, Choppin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997; 120: 1409-18
22. Choppin A, Eglen RM, Hegde SS. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br J Pharmacol 1998; 124: 883-8
23. Fetscher C, Fleichman M, Schmidt M, et al. M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002; 136: 641-4
24. Tobin G. Muscarinic receptor subtypes in the submandibular gland and the urinary bladder of the rabbit: in vivo and in vitro functional comparisons of receptor antagonists. J Auton Pharmacol 1995; 15: 451-63
25. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 48: 531-65
26. Choppin A, Eglen RM. Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br J Pharmacol 2001; 132: 835-42
27. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997; 157: 1093-7
28. Madersbacher H, Knoll M. Intravesical application of oxybutynin: mode of action controlling detrusor hypereflexia: preliminary results. Eur Urol 1995; 28: 340-4
29. Di Stasi SM, Giannantoni A, Navarra P, et al. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl-oxybutynin. J Urol 2001; 166: 2232-6
30. Yong C-L, Yu D, Eden L, et al. Effect of food on the pharmacokinetics of oxybutynin in normal subjects [abstract]. Pharm Res 1991; 8 Suppl.: S-320
31. Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988; 140: 47-50
32. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161: 1809-12
33. Versi E, Appell R. Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95: 718-21
34. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999; 54: 420-3
35. Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology 2002; 59: 428-32
36. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001; 185: 56-61
37. van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001; 57: 414-21
38. Chancellor MB, Appell RA, Sathyan G, et al. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther 2001; 23: 753-60
39. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358-63
40. Sussman D. Dry mouth is more pronounced in patients with overactive bladder treated with extended release oxybutynin compared to tolterodine [abstract]. Eur Urol Suppl 2002; 1: 133